Eterna Therapeutics announced positive preclinical results for its lead cell therapy product, ERNA-101, in treating ovarian cancer. The study showed increased T cell infiltration into the tumor, reduced tumor size, and improved survival rates in mice after a single dose of ERNA-101. The therapy successfully transitioned the tumor microenvironment from “cold” (low immune activity) to “hot” (high immune activity).
This preclinical success is a crucial advancement in ovarian cancer treatment, particularly for platinum-resistant cases where current options are limited. The ability of ERNA-101 to activate the immune system within the tumor itself offers a new approach, potentially overcoming the limitations of other immunotherapies. Furthermore, the demonstrated ability to convert a “cold” tumor “hot” suggests that ERNA-101 could be used in combination with other therapies like CAR-T and CAR-NK cell therapies to boost their effectiveness.
ERNA-101 utilizes induced pluripotent stem cells (iPSCs) to create induced allogenic mesenchymal stem cells (iMSCs) that secrete interleukins IL-7 and IL-15. These iMSCs are designed to infiltrate the tumor and deliver these cytokines directly, increasing localized immune response while minimizing systemic toxicity. The study, led by researchers at MD Anderson Cancer Center, involved an ovarian tumor model in mice. Treatment with ERNA-101 led to significantly higher T cell infiltration, reduced tumor size, and improved survival compared to control groups. Importantly, no significant weight differences were observed between the treated and control groups, suggesting a favorable safety profile in this preclinical setting.
These findings pave the way for further clinical investigation of ERNA-101. The positive results could potentially lead to a new treatment paradigm for ovarian cancer, offering hope for patients who have limited options. The potential for combination therapies with ERNA-101 further expands its impact, possibly improving outcomes for a broader range of cancer patients.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
